Has gestational hypertension been banished?

Contemporary OB/GYN JournalVol 64 No 9
Volume 64
Issue 9

Ob/gyns sometimes need to go beyond guidelines when making judgment calls, as is the case with whether to induce at 37 weeks for gestational hypertension.

Pregnant blood pressure

©didesign - stock.adobe.com

Table 1

Table 1

The diagnosis of gestational hypertension has been in our obstetric lexicon since at least 1976 when it was described in the 15th edition of Williams as “...hypertension that develops during the latter half of pregnancy or during the first 24 hours after delivery. It is not accompanied by other evidence of preeclampsia or hypertensive vascular disease, and it disappears within 10 days following parturition.”1 That edition of Williams went on to say that it is most likely a variant of preeclampsia. There is little in that edition on recommendations for management of women with gestational hypertension, but it is noted that “Bed rest throughout much of the day is essential…” for hospital management in women with pregnancy-induced hypertension.

I do not have an earlier version of Williams Obstetrics and if anyone does, please search for gestational hypertension and let me know what you find. But suffice it to say that most currently practicing ob/gyns accept gestational hypertension as a real entity and most would say that a significant proportion of women with gestational hypertension will develop preeclampsia at some time during pregnancy. Furthermore, the prevailing management of gestational hypertension includes ruling out preeclampsia, and if ruled out, outpatient observation with frequent blood pressure checks, visits to the provider office, fetal assessment, and delivery for development of preeclampsia, severe hypertension or by 39 weeks.2 Thus, the management was different for gestational hypertension than for preeclampsia, for which (depending on presence or absence of severe features) delivery was recommended at 34 (with severe features) or 37 weeks (without severe features). By the way, wasn’t it easier to just say (or type) mild preeclampsia rather than preeclampsia without severe features?

However, the American College of Obstetricians and Gynecologists (ACOG) has been struggling with what to recommend for management of women with gestational hypertension since the HYPITAT trial was published in 2009.3  This trial, performed in the Netherlands, randomized women with gestational hypertension or mild preeclampsia at 36 to 41 weeks’ gestation to induction of labor or expectant management. They reported that the women randomized to induction had a significantly lower rate of the maternal composite adverse outcome (i.e., HELLP (hemolysis, elevated liver enzymes, low platelet count), eclampsia, abruption, pulmonary edema, progression to severe disease, thromboembolic disease or major postpartum hemorrhage) (31%) than those in the expectant group (44%). Further, there was no difference in cesarean delivery rates or neonatal outcome. So it seems clearly reasonable to cite this paper as Level A evidence for the recommendation that all women with gestational hypertension should be induced at 37 weeks, not 37 completed weeks, but 37 0/7 weeks, which is the same recommendation for women with preeclampsia without severe features.4  Reasonable, right?  

What might give us pause, as noted above, the ACOG experts have struggled with this recommendation over the last 6 years, releasing multiple documents with varying guidelines for delivery timing for women with gestational hypertension (Table 1). In 2013 they even had two different recommendations in the same year. Do not be misled by my questioning of ACOG. I am a strong advocate of ACOG’s work and highly grateful for and respectful of the documents released as guidelines to help ob/gyns provide the best care based on ever-changing data.  

Sometimes, however, we have to use our own judgment and look a little deeper. In this example of the ACOG 2019 recommendation that women with either gestational hypertension or preeclampsia without severe features be managed exactly the same, suggesting that these are the same disease, I do take issue.4

Let me give you a few important details of the HYPITAT study mentioned above and used as the Level A evidence for this recommendation.

  • The diagnosis of gestational hypertension was diastolic blood pressure (DBP) ≥ 95 mmHg on two occasions, which is not a diagnosis that we use;

  • The only details about monitoring of the expectant group were “...frequent BP measurements, screening of urine for protein with dipstick or PC ratio” and fetal monitoring that was not clarified with regard to frequency;

  • Only 65% of women in both groups had gestational hypertension, the rest had preeclampsia;

  • The mean gestational age at randomization was 38 and a half weeks. So at least half of the patients in both groups were at least 38 weeks at time of delivery (not 37 weeks);

  • Although the maternal composite outcome was significantly less in the induced group, the only adverse outcome that really occurred in the expectant group was development of severe preeclampsia (36% vs. 23%). No woman developed eclampsia, an abruption or died, and there were no differences in neonatal outcome compared to women who were induced;

  • When the women with only gestational hypertension were analyzed, there was no difference in composite outcome between groups (31% vs 38%), while when the women with preeclampsia were analyzed separately, there remained a significant decrease in maternal composite outcome in the women induced compared to those expectantly managed (33% vs. 54%).

There is no doubt in my mind that women who develop gestational hypertension are at high risk of developing preeclampsia and potentially other morbidities associated with preeclampsia. The HYPITAT study tells us that half of the women in the expectant group were induced for severe disease. Further, gestational hypertension is associated with increased maternal and neonatal adverse outcomes compared to those in women who do not develop any hypertensive disease of pregnancy. In a large retrospective study, there was a significant increase in fetal growth restriction, postpartum hemorrhage, and maternal intensive care unit (ICU) admission in women with gestational hypertension compared to women without hypertension.5 So these women deserve very careful evaluation and follow-up, which for most of us would mean at least twice-weekly visits for fetal and maternal assessment, home BP monitoring, and clear instructions for when to come in or to call. And certainly, some of them should be induced at 37 0/7 weeks? Perhaps if we cannot ensure follow-up or if a woman has another morbidity like underlying medical disease or fetal growth restriction. But, what if her baseline BPs all along have been in the 130s/80s and then at her 37-week visit she has a BP of 140/80, which you repeat 4 hours later and find is 138/90. You rule out preeclampsia. Do you tell her she must be induced?  

You can tell what I will say: Counsel her, provide excellent instructions for follow-up and a plan for when you would induce her. I say she has gestational hypertension that is not yet preeclampsia. I say this is not the same disease as preeclampsia even if gestational hypertension is on a continuum with a 50% chance of developing preeclampsia. I say ACOG documents are important and useful guidelines, but they are not “the law” (Table 1).4,6,7 I say we are physicians with many years of experience and must use our judgement when making medical recommendations and we must document these discussions and recommendations. What would I do if a woman with gestational hypertension presents at 37 0/7 weeks with a BP of 160/100 and no other sign or symptom of preeclampsia? I would induce. And in between these numbers, what should you do? You know.


I hope that we really haven’t banished the diagnosis of gestational hypertension after all these years and that ACOG keeps providing guidelines and we keep using our judgement to provide the best care we can for women.


The author reports no potential conflicts of interest with regard to this editorial.


  • Pritchard JA, MacDonald PC. Williams Obstetrics. New York: Appleton-Century-Crofts, 1976.

  • Spong CY, Mercer BM, D’Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011;118:323-333. 

  • Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ et al.  Induction of labour versus expectant monitoring for gestational hypertension or mild preeclampsia after 36 weeks’ gestation (HYPITAT): a multicenter, open label randomized controlled trial. HYPITAT study group. Lancet. 2009;374:979-988.

  • American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133:e1-25. 

  • Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. Am J Obstet Gynecol. 2011;205:260 e1-9. 

  • American College of Obstetricians and Gynecologists. ACOG committee opinion no. 560: Medically indicated late-preterm and early term deliveries. Obstet Gynecol. 2013;121:908-10. (reaffirmed in 2015)

  • American College of Obstetricians and Gynecologists. Executive summary: hypertension in pregnancy. Obstet Gynecol. 2013;122:1122-1131.
Related Videos
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
raanan meyer, md
The impact of smoking cessation on pregnancy outcomes | Image Credit: rwjmg.rwjms.rutgers.edu
Maximizing maternal health: The impact of exercise during pregnancy | Image Credit: cedars-sinai.org
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.